Judicial review of biotech approvals

Introduction

Judicial review of biotech approvals refers to the power of courts to examine whether governmental and regulatory authorities have lawfully, rationally, and procedurally approved biotechnology products, activities, clinical applications, genetically modified organisms, biological medicines, vaccines, or other biotech interventions.

Biotechnology approvals often involve highly technical scientific assessments. Courts therefore generally do not substitute their own scientific opinion for that of specialised regulators. However, technical expertise does not place regulatory decisions beyond judicial review. Courts can examine legality, procedural fairness, jurisdiction, relevant considerations, scientific rationality, environmental risks, and constitutional rights.

The principal challenge is maintaining a balance between regulatory expertise and judicial accountability.

Meaning and scope

Biotech approvals can involve multiple regulatory decisions, including approval of genetically modified organisms, pharmaceutical products, vaccines, clinical trials, medical devices, gene therapies, and environmental releases.

Judicial review may examine whether the authority:

• acted within its statutory powers;
• followed the prescribed approval procedure;
• considered relevant scientific evidence;
• ignored material risks;
• applied the precautionary principle where legally applicable;
• provided adequate reasons;
• complied with environmental and constitutional requirements;
• acted without arbitrariness or mala fides.

The court generally reviews the decision-making process rather than conducting the scientific approval itself.

Judicial review and specialised expertise

Courts frequently recognise that regulatory agencies possess specialised scientific expertise.

In National Association of Home Builders v. Defenders of Wildlife (2007), the U.S. Supreme Court considered the interaction between statutory requirements and agency decision-making. The case demonstrates the broader principle that an agency must exercise its statutory authority consistently with legislative requirements.

In biotechnology, a regulator cannot rely on scientific expertise as a substitute for compliance with the governing statute.

Similarly, in Chevron U.S.A. Inc. v. Natural Resources Defense Council, Inc. (1984), the U.S. Supreme Court developed principles concerning judicial treatment of administrative agency interpretations. Although the precise doctrine has subsequently been reconsidered in U.S. law, the case remains historically important for understanding judicial deference to specialised agencies.

The broader lesson is that expertise may justify institutional deference, but it does not eliminate judicial oversight.

Monsanto Co. v. Geertson Seed Farms

One of the most important biotechnology-related cases is Monsanto Co. v. Geertson Seed Farms (2010).

The litigation concerned the U.S. Department of Agriculture's regulatory treatment of genetically engineered alfalfa. The Supreme Court considered whether the agency had adequately complied with environmental-review requirements.

The case demonstrates that courts can intervene when a regulatory authority fails to satisfy mandatory environmental procedures, even where the underlying biotechnology is scientifically complex.

The significance of the decision is that scientific uncertainty does not automatically excuse an agency from complying with statutory environmental obligations.

International environmental principles

Biotech approvals may also have environmental consequences, particularly where genetically modified organisms or engineered biological materials may be released into ecosystems.

In Vellore Citizens' Welfare Forum v. Union of India (1996), the Supreme Court of India recognised the importance of the precautionary principle and the polluter-pays principle within Indian environmental jurisprudence.

The precautionary principle is particularly relevant to biotechnology where scientific uncertainty exists concerning long-term ecological effects.

A regulator may therefore be required to consider reasonably foreseeable environmental risks before approving activities capable of causing significant harm.

A.P. Pollution Control Board v. Prof. M.V. Nayudu

In A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999), the Supreme Court of India discussed the difficulties courts face when resolving highly technical environmental and scientific questions.

The Court recognised the need for specialised scientific expertise in complex environmental disputes.

This principle is directly relevant to biotech approvals. Courts may need independent scientific assistance when evaluating complicated technical questions, while still retaining responsibility for determining whether the regulatory process was lawful.

The case therefore supports a model of informed judicial review rather than unrestricted judicial substitution of scientific judgment.

Precautionary principle and biotech approvals

The precautionary principle becomes important where a biotech approval involves uncertain but potentially serious risks.

A court may ask:

• Was the potential risk identified?
• Was relevant scientific evidence considered?
• Were alternatives examined?
• Was risk assessment performed properly?
• Were appropriate safeguards imposed?
• Did the authority explain why approval remained justified?

The court does not necessarily have to prove that harm will occur. The issue may instead be whether the regulator reasonably addressed scientifically credible risks.

Administrative law and reasoned decisions

Biotech approval decisions should ordinarily contain sufficient reasoning to demonstrate that the regulator considered relevant factors.

A decision may become vulnerable to judicial review if an authority:

• ignores material scientific evidence;
• relies on irrelevant considerations;
• fails to apply mandatory statutory criteria;
• acts arbitrarily;
• provides no meaningful explanation;
• improperly delegates its statutory responsibility.

Reasoned decision-making is particularly important in biotechnology because the underlying scientific material may be difficult for affected individuals and communities to understand.

Judicial review in India

Indian administrative law provides several constitutional mechanisms through Articles 32 and 226.

Courts may examine whether regulatory authorities have acted:

• without jurisdiction;
• arbitrarily;
• in violation of natural justice;
• contrary to statutory requirements;
• irrationally or unreasonably;
• for an improper purpose.

The doctrine of Wednesbury unreasonableness, developed in Associated Provincial Picture Houses Ltd. v. Wednesbury Corporation (1948), remains an important historical foundation for reviewing unreasonable administrative decisions.

However, Indian constitutional review has also developed broader proportionality principles, particularly where fundamental rights are affected.

Natural justice

Biotech approvals may affect patients, research participants, environmental groups, competitors, manufacturers, and local communities.

Where legislation requires notice, consultation, hearings, or disclosure, failure to follow those requirements may make an approval vulnerable to judicial review.

The Supreme Court's decision in Maneka Gandhi v. Union of India (1978) significantly strengthened the relationship between administrative fairness and constitutional protections under Article 21.

Consequently, a regulatory process affecting important rights cannot necessarily be justified merely because the final decision appears scientifically reasonable.

Clinical and pharmaceutical approvals

Judicial review may also concern pharmaceutical and clinical-trial decisions.

In Association of Medical Superintendents of Government Hospitals v. various Indian authorities, courts have repeatedly emphasised the importance of informed consent and patient protection in medical experimentation. More generally, Indian constitutional jurisprudence requires regulatory systems involving human subjects to respect dignity, autonomy, and informed consent.

Courts may therefore scrutinise whether regulators adequately considered:

• participant safety;
• informed consent;
• clinical evidence;
• adverse-event data;
• ethical review;
• manufacturing standards.

Judicial restraint

Judicial review does not mean that judges become substitute biotechnology regulators.

A court should generally avoid deciding purely scientific questions merely because another scientific conclusion appears possible.

Instead, the court should ask whether the regulator's conclusion had a rational evidentiary foundation and whether the statutory decision-making process was properly followed.

This distinction is crucial:

Judicial review: Was the approval lawful, rational, procedurally fair, and scientifically supported?

Scientific substitution: Which biotechnology product or scientific conclusion is actually correct?

The first falls naturally within judicial review; the second may exceed the institutional role of the court.

Conclusion

Judicial review of biotech approvals provides an essential mechanism for ensuring that biotechnology regulators remain accountable while preserving appropriate respect for scientific expertise.

Important authorities include Monsanto Co. v. Geertson Seed Farms (2010), Vellore Citizens' Welfare Forum v. Union of India (1996), A.P. Pollution Control Board v. M.V. Nayudu (1999), Maneka Gandhi v. Union of India (1978), Associated Provincial Picture Houses v. Wednesbury Corporation (1948), and National Association of Home Builders v. Defenders of Wildlife (2007).

The governing principle can be stated as follows:

Courts should not ordinarily replace scientific regulators, but scientific complexity cannot shield unlawful, irrational, procedurally defective, or inadequately reasoned biotech approvals from judicial review.

Effective judicial review therefore requires a careful balance between scientific deference and legal accountability, ensuring that biotech approvals are based on lawful authority, reliable evidence, procedural fairness, proportionality, environmental protection, and protection of fundamental rights.